This Mentored Patient-Oriented Research Career Development Award will prepare a pediatric neuroophthalmologist for an academic career as an independent multidisciplinary clinical researcher with a focus on vision outcomes in children with brain tumors of the visual pathway called optic pathway gliomas (OPGs). The candidate's application provides training needed to establish a clinical research career committed to using novel ophthalmologic imaging methods that serve as a surrogate marker of visual acuity (VA) for children with OPGs. The candidate is proposing multidisciplinary mentorship from a pediatric ophthalmologist lead comentor, biostatistician lead co-mentor, and distinguished panel of expert consultants in neuro-oncology, glaucoma and ophthalmologic imaging. This application addresses goals outlined in the NEI's Framework for Vision Research, specifically goal 3.2 Develop and validate biomarkers that are useful in diagnosing and stratifying patients, measuring disease progression and gauging therapeutic outcomes. OPGs can cause significant permanent VA loss in children, typically between the ages of 1 and 8 years of age. Treatment of OPGs with chemotherapy is only initiated once new or progressive VA loss has been detected in an attempt to preserve or improve vision. However, accurately measuring VA in children is highly dependent upon their cooperation and many young children with OPGs are frequently unable to cooperate with VA testing due to associated behavioral problems. Therefore, a reliable quantitative biomarker of VA that does not rely on patient cooperation is desperately needed in children with OPGs. The retinal nerve fiber layer (RNFL) is the most proximal region of the visual pathway and prior studies have shown that VA is closely correlated to RNFL thickness. Specifically, as RNFL thickness declines, VA also diminishes. Optical coherence tomography (OCT), an optical analog of ultrasound imaging, can safely measure RNFL thickness, but also requires patient cooperation. This proposal remedies the difficulty in acquiring RNFL measures in infants/young children who cannot cooperate for OCT, by using a hand-held spectral domain OCT (HH-OCT) while sedated for a MRI scan. HH-OCT imaging protocols targeted specifically for the very young-who are at the highest risk for VA loss from their OPG-will establish RNFL thickness as a quantitative biomarker of VA. Two cross-sectional studies of children with and without OPGs will establish the structure-function relationship between VA and RNFL thickness, as measured by HH-OCT. A third study will analyze longitudinal changes in VA and RNFL thickness in children with OPGs. These studies will establish RNFL thickness as a quantitative biomarker of VA and improve our ability to make crucial treatment decisions in children with OPGs. The ability to detect impending vision loss will allow us to provide early treatment with the hope of preventing vision loss.

Public Health Relevance

Low-grade gliomas, the most common type of brain tumor in children, can cause severe vision loss in some, but not all of the children with these tumors. Treatment with chemotherapy is only initiated after vision loss has occurred, but unfortunately young children with these tumors are frequently uncooperative with their vision testing. The goal of this project is to use novel ophthalmologic imaging methods that do not require patient cooperation as a surrogate marker of vision which may allow for early detection and treatment of impending vision loss.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
7K23EY022673-05
Application #
9176057
Study Section
Special Emphasis Panel (ZEY1-VSN (10))
Program Officer
Agarwal, Neeraj
Project Start
2015-12-01
Project End
2017-07-31
Budget Start
2015-12-01
Budget End
2016-07-31
Support Year
5
Fiscal Year
2015
Total Cost
$228,593
Indirect Cost
$16,933
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
de Blank, Peter M K; Fisher, Michael J; Liu, Grant T et al. (2017) Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. J Neuroophthalmol 37 Suppl 1:S23-S32
Beres, Shannon Jeanine; Avery, Robert A (2017) Optic Pathway Gliomas Secondary to Neurofibromatosis Type 1. Semin Pediatr Neurol 24:92-99
Avery, Robert A; Katowitz, James A; Fisher, Michael J et al. (2017) Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Multidisciplinary Recommendations for Care. Ophthalmology 124:123-132
Trimboli-Heidler, Carmelina; Vogt, Kelly; Avery, Robert A (2016) Volume Averaging of Spectral-Domain Optical Coherence Tomography Impacts Retinal Segmentation in Children. Transl Vis Sci Technol 5:12
Avery, Robert A; Trimboli-Heidler, Carmelina; Kilburn, Lindsay B (2016) Separation of outer retinal layers secondary to selumetinib. J AAPOS 20:268-71
Avery, Robert A; Cnaan, Avital; Schuman, Joel S et al. (2015) Longitudinal Change of Circumpapillary Retinal Nerve Fiber Layer Thickness in Children With Optic Pathway Gliomas. Am J Ophthalmol 160:944-952.e1
Narula, Sona; Liu, Grant T; Avery, Robert A et al. (2015) Elevated cerebrospinal fluid opening pressure in a pediatric demyelinating disease cohort. Pediatr Neurol 52:446-9
Rajjoub, Raneem D; Trimboli-Heidler, Carmelina; Packer, Roger J et al. (2015) Reproducibility of retinal nerve fiber layer thickness measures using eye tracking in children with nonglaucomatous optic neuropathy. Am J Ophthalmol 159:71-7.e1
Bruce, Beau B (2014) Noninvasive assessment of cerebrospinal fluid pressure. J Neuroophthalmol 34:288-94
Avery, Robert A; Hwang, Eugene I; Jakacki, Regina I et al. (2014) Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol 132:111-4

Showing the most recent 10 out of 20 publications